Compass Pathways reports six-month results from its second Phase 3 trial, saying psilocybin treatment produced rapid and durable effects in treatment-resistant depression

Compass Pathways reports six-month data from a second Phase 3 trial of its psilocybin treatment in people with treatment-resistant depression, highlighting a rapid onset of benefit and effects that remained durable over time. The focus is late-stage clinical development of a psychedelic-assisted mental health treatment and whether results replicate earlier findings. The update centers on longer-term outcomes rather than only acute response, which is critical for regulators, clinicians, and investors assessing real-world therapeutic value. Treatment-resistant depression remains a major unmet need, so evidence that symptom improvement can persist for six months strengthens the case for a scalable intervention if safety and efficacy continue to hold. The announcement also matters commercially because Phase 3 confirmation can shape timelines for regulatory submission, market positioning, and broader confidence in the psychedelic medicine sector. Durable follow-up data are especially important in distinguishing one-time or limited-dose approaches from chronic daily psychiatric medication models.